Alternative splicing in prostate cancer

Alec Paschalis, Adam Sharp, Jonathan C. Welti, Antje Neeb, Ganesh V. Raj, Jun Luo, Stephen R. Plymate, Johann S. de Bono

Research output: Contribution to journalReview article

Abstract

Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development and progression of metastatic prostate cancer. AR-Vs are truncated isoforms of the AR, a subset of which lack a ligand-binding domain and remain constitutively active in the absence of circulating androgens, thus promoting cancer cell proliferation. Consequently, AR-Vs have been proposed to contribute not only to resistance to anti-androgen therapies but also to resistance to radiotherapy in patients receiving combination therapy by promoting DNA repair. AR-Vs, such as AR-V7, have been associated with unfavourable clinical outcomes in patients; however, attempts to specifically inhibit or prevent the formation of AR-Vs have, to date, been unsuccessful. Thus, novel therapeutic strategies are desperately needed to address the oncogenic effects of AR-Vs, which can drive lethal forms of prostate cancer. Disruption of alternative splicing through modulation of the spliceosome is one such potential therapeutic avenue; however, our understanding of the biology of the spliceosome and how it contributes to prostate cancer remains incomplete, as reflected in the dearth of spliceosome-targeted therapeutic agents. In this Review, the authors outline the current understanding of the role of the spliceosome in the progression of prostate cancer and explore the therapeutic utility of manipulating alternative splicing to improve patient care.

Original languageEnglish (US)
Pages (from-to)663-675
Number of pages13
JournalNature Reviews Clinical Oncology
Volume15
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Alternative Splicing
Androgen Receptors
Prostatic Neoplasms
Spliceosomes
Androgens
Therapeutics
DNA Repair
Patient Care
Protein Isoforms
Radiotherapy
Cell Proliferation
Ligands

ASJC Scopus subject areas

  • Oncology

Cite this

Paschalis, A., Sharp, A., Welti, J. C., Neeb, A., Raj, G. V., Luo, J., ... de Bono, J. S. (2018). Alternative splicing in prostate cancer. Nature Reviews Clinical Oncology, 15(11), 663-675. https://doi.org/10.1038/s41571-018-0085-0

Alternative splicing in prostate cancer. / Paschalis, Alec; Sharp, Adam; Welti, Jonathan C.; Neeb, Antje; Raj, Ganesh V.; Luo, Jun; Plymate, Stephen R.; de Bono, Johann S.

In: Nature Reviews Clinical Oncology, Vol. 15, No. 11, 01.11.2018, p. 663-675.

Research output: Contribution to journalReview article

Paschalis, A, Sharp, A, Welti, JC, Neeb, A, Raj, GV, Luo, J, Plymate, SR & de Bono, JS 2018, 'Alternative splicing in prostate cancer', Nature Reviews Clinical Oncology, vol. 15, no. 11, pp. 663-675. https://doi.org/10.1038/s41571-018-0085-0
Paschalis A, Sharp A, Welti JC, Neeb A, Raj GV, Luo J et al. Alternative splicing in prostate cancer. Nature Reviews Clinical Oncology. 2018 Nov 1;15(11):663-675. https://doi.org/10.1038/s41571-018-0085-0
Paschalis, Alec ; Sharp, Adam ; Welti, Jonathan C. ; Neeb, Antje ; Raj, Ganesh V. ; Luo, Jun ; Plymate, Stephen R. ; de Bono, Johann S. / Alternative splicing in prostate cancer. In: Nature Reviews Clinical Oncology. 2018 ; Vol. 15, No. 11. pp. 663-675.
@article{7f01386c797c47b3a3acc46589befe6b,
title = "Alternative splicing in prostate cancer",
abstract = "Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development and progression of metastatic prostate cancer. AR-Vs are truncated isoforms of the AR, a subset of which lack a ligand-binding domain and remain constitutively active in the absence of circulating androgens, thus promoting cancer cell proliferation. Consequently, AR-Vs have been proposed to contribute not only to resistance to anti-androgen therapies but also to resistance to radiotherapy in patients receiving combination therapy by promoting DNA repair. AR-Vs, such as AR-V7, have been associated with unfavourable clinical outcomes in patients; however, attempts to specifically inhibit or prevent the formation of AR-Vs have, to date, been unsuccessful. Thus, novel therapeutic strategies are desperately needed to address the oncogenic effects of AR-Vs, which can drive lethal forms of prostate cancer. Disruption of alternative splicing through modulation of the spliceosome is one such potential therapeutic avenue; however, our understanding of the biology of the spliceosome and how it contributes to prostate cancer remains incomplete, as reflected in the dearth of spliceosome-targeted therapeutic agents. In this Review, the authors outline the current understanding of the role of the spliceosome in the progression of prostate cancer and explore the therapeutic utility of manipulating alternative splicing to improve patient care.",
author = "Alec Paschalis and Adam Sharp and Welti, {Jonathan C.} and Antje Neeb and Raj, {Ganesh V.} and Jun Luo and Plymate, {Stephen R.} and {de Bono}, {Johann S.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1038/s41571-018-0085-0",
language = "English (US)",
volume = "15",
pages = "663--675",
journal = "Nature Clinical Practice Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Alternative splicing in prostate cancer

AU - Paschalis, Alec

AU - Sharp, Adam

AU - Welti, Jonathan C.

AU - Neeb, Antje

AU - Raj, Ganesh V.

AU - Luo, Jun

AU - Plymate, Stephen R.

AU - de Bono, Johann S.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development and progression of metastatic prostate cancer. AR-Vs are truncated isoforms of the AR, a subset of which lack a ligand-binding domain and remain constitutively active in the absence of circulating androgens, thus promoting cancer cell proliferation. Consequently, AR-Vs have been proposed to contribute not only to resistance to anti-androgen therapies but also to resistance to radiotherapy in patients receiving combination therapy by promoting DNA repair. AR-Vs, such as AR-V7, have been associated with unfavourable clinical outcomes in patients; however, attempts to specifically inhibit or prevent the formation of AR-Vs have, to date, been unsuccessful. Thus, novel therapeutic strategies are desperately needed to address the oncogenic effects of AR-Vs, which can drive lethal forms of prostate cancer. Disruption of alternative splicing through modulation of the spliceosome is one such potential therapeutic avenue; however, our understanding of the biology of the spliceosome and how it contributes to prostate cancer remains incomplete, as reflected in the dearth of spliceosome-targeted therapeutic agents. In this Review, the authors outline the current understanding of the role of the spliceosome in the progression of prostate cancer and explore the therapeutic utility of manipulating alternative splicing to improve patient care.

AB - Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development and progression of metastatic prostate cancer. AR-Vs are truncated isoforms of the AR, a subset of which lack a ligand-binding domain and remain constitutively active in the absence of circulating androgens, thus promoting cancer cell proliferation. Consequently, AR-Vs have been proposed to contribute not only to resistance to anti-androgen therapies but also to resistance to radiotherapy in patients receiving combination therapy by promoting DNA repair. AR-Vs, such as AR-V7, have been associated with unfavourable clinical outcomes in patients; however, attempts to specifically inhibit or prevent the formation of AR-Vs have, to date, been unsuccessful. Thus, novel therapeutic strategies are desperately needed to address the oncogenic effects of AR-Vs, which can drive lethal forms of prostate cancer. Disruption of alternative splicing through modulation of the spliceosome is one such potential therapeutic avenue; however, our understanding of the biology of the spliceosome and how it contributes to prostate cancer remains incomplete, as reflected in the dearth of spliceosome-targeted therapeutic agents. In this Review, the authors outline the current understanding of the role of the spliceosome in the progression of prostate cancer and explore the therapeutic utility of manipulating alternative splicing to improve patient care.

UR - http://www.scopus.com/inward/record.url?scp=85052958753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052958753&partnerID=8YFLogxK

U2 - 10.1038/s41571-018-0085-0

DO - 10.1038/s41571-018-0085-0

M3 - Review article

VL - 15

SP - 663

EP - 675

JO - Nature Clinical Practice Oncology

JF - Nature Clinical Practice Oncology

SN - 1759-4774

IS - 11

ER -